Product/Presentation number | Abstract title and scheduled presentation date and time |
Presentations | |
Elenbecestat Session No.: OC5 | Elenbecestat in MCI-to-Moderate Alzheimer's Disease: Safety and Effectiveness as Measured by Amyloid PET and the ADCOMS Clinical Endpoints October 25, (Thurs) 9:30 AM – 9:45 AM CEST |
Aducanumab Session No.: Keynote 2 | What have we Learned from Aducanumab? October 25, (Thurs) 1:30 PM - 2:00 PM CEST |
BAN2401 Session No.: Symposium 3 | Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD October 25, (Thurs) 2:30 PM – 3:30 PM CEST |
Lemborexent Session No.: OC11 | Safety and Efficacy of Lemborexant for Sleep-Wake Regulation in Patients with Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia October 25, (Thurs) 3:30 PM – 3:45 PM CEST |
Aducanumab Session No.: LB8 | Aducanumab Titration Dosing Regimen: 36-Month Analyses From PRIME, A Phase 1B Study in Patients with Early Alzheimer's Disease October 26, (Fri) 3:15 PM - 3:30 PM CEST |
Poster Presentations | |
Aducanumab Poster No.: P80 | Cumulative Aducanumab Safety Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study October 24, (Wednesday) – October 27, (Saturday) |
Aducanumab Poster No.: LBP19 | Aducanumab 48-Month Analyses from PRIME, a Phase 1B Study in Patients with Early Alzheimer's Disease October 24, (Wednesday) - October 27, (Saturday) |
